Scholarlink

Background <p><i>BRCA1</i> and <i>BRCA2</i> are tumor suppressor genes essential for DNA repair. Mutations in these genes significantly increase breast (BC) and ovarian cancer (OC) risk, with <i>BRCA1</i>-positive facing a 70% BC and 40% OC lifetime risk. While guidelines for BRCA-positive are well established, recommendations for BC surveillance in <i>BRCA</i>-patients already diagnosed with OC remain limited. This meta-analysis evaluates BC risk post-OC in <i>BRCA</i>-mutated women.</p> Methods <p>A systematic search of PubMed, Embase, and the Cochrane Library was performed. Single-arm outcomes were pooled using meta-analysis of proportions, and survival data were synthesized using hazard ratio (HR), both with 95% confidence intervals (CIs). Heterogeneity was assessed using the I² statistic. All analyses were conducted in R (version 4.3.2).</p> Results <p>A total of 2380 patients from 10 retrospective cohort studies were included. Among them, 181 (8%; 95% CI: 6%–11%) developed BC post-OC, with similar rates observed for <i>BRCA1</i> and <i>BRCA2</i>-mutated (9%; 95% CI: 7%–12%). In overall survival analysis, <i>BRCA</i>-mutated patients who developed BC after OC had significantly improved outcomes compared to those with OC only (HR = 0.4657; <i>P</i> &lt; 0.001).</p> Conclusion <p>This meta-analysis underscores the need for tailored BC surveillance and evidence-based screening guidelines in <i>BRCA</i>-mutated OC survivors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Breast cancer incidence and subtype patterns among BRCA-mutated ovarian cancer patients: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年12月23日

查看全文
  • Pedro Henrique de Souza Wagner,
  • Gustavo Tadeu Freitas Uchôa Matheus,
  • Danilo Monteiro Ribeiro,
  • Maria Cristina Figueroa Magalhães,
  • Francisco Cezar Aquino de Moraes

摘要

Background

BRCA1 and BRCA2 are tumor suppressor genes essential for DNA repair. Mutations in these genes significantly increase breast (BC) and ovarian cancer (OC) risk, with BRCA1-positive facing a 70% BC and 40% OC lifetime risk. While guidelines for BRCA-positive are well established, recommendations for BC surveillance in BRCA-patients already diagnosed with OC remain limited. This meta-analysis evaluates BC risk post-OC in BRCA-mutated women.

Methods

A systematic search of PubMed, Embase, and the Cochrane Library was performed. Single-arm outcomes were pooled using meta-analysis of proportions, and survival data were synthesized using hazard ratio (HR), both with 95% confidence intervals (CIs). Heterogeneity was assessed using the I² statistic. All analyses were conducted in R (version 4.3.2).

Results

A total of 2380 patients from 10 retrospective cohort studies were included. Among them, 181 (8%; 95% CI: 6%–11%) developed BC post-OC, with similar rates observed for BRCA1 and BRCA2-mutated (9%; 95% CI: 7%–12%). In overall survival analysis, BRCA-mutated patients who developed BC after OC had significantly improved outcomes compared to those with OC only (HR = 0.4657; P < 0.001).

Conclusion

This meta-analysis underscores the need for tailored BC surveillance and evidence-based screening guidelines in BRCA-mutated OC survivors.